State of art and recent developments of anti-cancer strategies based on TRAIL

Recent Patents on Anti-Cancer Drug Discovery

Volumn 7, Issue 2, 2012, Pages 207-217

  Bernardi, Stella ^a   Secchiero, Paola ^a   Zauli, Giorgio ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

Apoptosis; Apoptosis resistance; Combination therapy; Death receptors agonists; Extrinsic apoptotic pathway; Safety; TRAIL; TRAIL mimetics

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CONATUMUMAB; DACINOSTAT; DOXORUBICIN; DROZITUMAB; DULANERMIN; FLUOROURACIL; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; LBY 135; LEXATUMUMAB; MAPATUMUMAB; OBLIMERSEN; PACLITAXEL; PRO 1762; PROAPOPTOTIC RECEPTOR AGONIST; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SORAFENIB; TIGATUZUMAB; TRA 8; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CELL CYCLE ARREST; CHONDROSARCOMA; COLON CANCER; COLORECTAL CANCER; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; GLIOMA; HUMAN; INTRACELLULAR SIGNALING; KIDNEY TUMOR; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; HUMANS; MICE; NEOPLASMS; RECEPTORS, DEATH DOMAIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84860289378     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489212799972927     Document Type: Review

References (142)

1. International agency for Research on Cancer, World Health Organization Website. Available at http://globocan.iarc.fr (Accessed on July 18th 2011).
2. Adams JM, Cory S. Bcl-2-regulated apoptosis: Mechanism and therapeutic potential. Curr Opin Immunol 2007; 19(5): 488-96.
3. Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000; 406(6798): 855-62.
4. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000; 408(6815): 1008-12.
5. Ozoren N, El-Deiry WS. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 2002; 4(6): 551-7.
6. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3(6): 673-82.
7. Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004; 201(3): 331-40.
8. Secchiero P, Zauli G. TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Op Hematol 2008; 15(1): 42-8.
9. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168(3): 1356-61.
10. Sedger LM, Glaccum MB, Schuh JC, Kanaly ST, Williamson E, Kayagaki, N, et al. Characterization of the in vivo function of TNFalpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 2002; 32(8): 2246-54.
11. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005; 434(7029): 88-93.
12. Wang S, El-Deiry WS. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 2004; 64(18): 6666-72.
13. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276(5309): 111-3.
14. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277(5327): 815-8.
15. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277(5327): 818-21.
16. Wu GS, Burns TF, McDonald ER, 3rd, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17(2): 141-3.
17. Milani D, Zauli G, Rimondi E, Celeghini C, Marmiroli S, Narducci P, et al. Tumor necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 2003; 86(1): 126-35.
18. Harper N, Farrow SN, Kaptein A, Cohen GM, MacFarlane M. Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-kappa B activation by inhibition of apical caspases. J Biol Chem 2001; 276(37): 34743-52.
19. Secchiero P, Milani D, Gonelli A, Melloni E, Campioni D, Gibellini G, et al. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells. J Leukoc Biol 2003; 74(2): 223-32.
20. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003; 107(17): 2250-6.
21. Zauli G, Sancilio S, Cataldi A, Sabatini N, Bosco D, Di Pietro R. PI-3K/Akt and NF-K{green}B/IK{green}Bα pathways are activated in Jurkat T cells in response to TRAIL treatment. J Cell Physiol 2005; 202 (3): 900-11.
22. Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, et al. Evidence for a role of TNF-related apoptosisinducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 2005; 166(2): 557-63.
23. Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 2007; 8(4): 395-403.
24. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang, CP, DuBose RF, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186(7): 1165-70.
25. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NFkappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7(6): 813-20.
26. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7(12): 1003-6.
27. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 2009; 66(5): 841-51.
28. Zauli G, Corallini F, Bossi F, Fischietti F, Durigotto P, Celeghini C, et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007; 110(2): 536-43.
29. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104(2): 155-62.
30. Zauli G, Secchiero P. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 2006; 17(4): 245-57.
31. Lincz LF, Yeh TX, Spencer A. TRAIL-induced eradication of primary Tumor cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 2001; 15(10): 1650-7.
32. Wuchter C, Krappmann D, Cai Z, Ruppert V, Scheidereit C, Dorken B, et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia 2001; 15(6): 921-8.
33. Mirandola P, Ponti C, Gobbi G, Sponzilli I, Vaccarezza M, Cocco L, et al. Activated human NK and CD8+ T cells express both TNFrelated apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood 2004; 104(8): 2418-24.
34. Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006; 169(6): 2236-44.
35. Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6(2): 335-46.
36. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
37. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2(5): 574-7.
38. Friesen C, Fulda S, Debatin KM. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 1997; 11(11): 1833-41.
39. Ashkenazi A, Herbst RS. To kill a tumor cell: The potential of proapoptotic receptor agonists. J Clin Invest 2008; 118(6): 1979-90.
40. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358(6381): 15-6.
41. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous Tumors. Nature 1992; 356(6366): 215-21.
42. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003; 22(47):7414-30.
43. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene 2004; 23(16): 2934-49.
44. Secchiero P, di Iasio MG, Gonelli A, Zauli G. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des 2008; 14(21): 2100-10.
45. Secchiero P, Corallini F, Gonelli A, Dell'Eva R, Vitale M, Capitani S, et al. Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 2007; 100(1): 61-9.
46. Secchiero P, Zerbinati C, Melloni E, Milani D, Campioni D, Fadda R, et al. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. Neoplasia 2007; 9(10): 853-61.
47. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006; 108(3): 993-1000.
48. Secchiero P, Melloni E, di Iasio MG, Tiribelli M, Rimondi E, Corallini F, et al. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood 2009; 113(18): 4300-8.
49. Scott FL, Stec B, Pop C, Dobaczewska MK, Lee JJ, Monosov E, et al. The Fas-FADD death domain complex structure unravels signaling by receptor clustering. Nature 2009; 457 (7232): 1019-22.
50. Berg D, Lehne M, Muller N, Siegmund D, Munkel S, Sebald W, et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL andCD95L. Cell Death Differ 2007; 14(12): 2021-34.
51. Poh TW, Huang S, Hirpara JL, Pervaiz S. LY303511 amplifies TRAIL induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization. Cell Death Differ 2007; 14 (10): 1813-25.
52. Brimmell M, Mendiola R, Mangion J, Packham G. BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 1998; 16(14): 1803-12.
53. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275(5302): 967-9.
54. Reed, J. Antisense oligonucleotides inhibiting human Bcl-2 gene expression. US5734033 (1998).
55. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58(23): 5315-20.
56. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer antiapoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998; 152(1): 43-9.
57. Ciesielski, M.J., Fenstermaker, R.A. Survivin peptides as cancer vaccines. US20090041732 (2009).
58. Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res 2004; 64(24): 9105-14.
59. Nagata S. Apoptosis by death factor. Cell 1997; 88(3): 355-65.
60. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992; 13(5): 151-3.
61. Verbrugge I, Wissink EH, Rooswinkel RW, Jongsma J, Beltraminelli N, Dupuis M, et al. Combining radiotherapy with APO010 in cancer treatment. Clin Cancer Res 2009; 15(6): 2031-8.
62. Shiraishi T, Suzuyama K, Okamoto H, Mineta T, Tabuchi K, Nakayama K, et al. Increased cytotoxicity of soluble Fas ligand by fusing isoleucine zipper motif. Biochem Biophys Res Commun 2004; 322(1): 197-202.
63. Rosat, J.-P. Method for the administration of ligands, agonists of ligands of the TNF family with reduced toxicity. US20050143297 (2005).
64. Rasmussen H, Rasmussen C, Lempicki M, Durham R, Brough D, King CR, et al. TNFerade Biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 2002; 9(11): 951-7.
65. Ohno, T., Weichselbaum, R.R., Kufe, D.W. Method of inducing gene expression by ionizing radiation. US5571797 (1996).
66. Ashkenazi, A.J. Apo-2 ligand. US6030945 (2000).
67. Wiley, S.R., Goodwin, R.G. Cytokine that induce apoptosis. US6284236 (2001).
68. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 2001; 166(8): 4891-8.
69. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7(8): 954-60.
70. Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: Induction of apoptosis and enhancement of doxorubicin-and bortezomib-induced cell death. Br J Haematol 2005; 130(4): 501-10.
71. Ashkenazi, A.J., Chuntharapai, A., Kim, K.J. Method for making monoclonal antibodies and cross-reactive antbodies obtainable by the method. US6252050 (2001).
72. Salcedo, T., Roschke, V., Rosen, C.A., Ruben, S.M. Antibodies that immunospecifically bind to TRAIL. US20030228309 (2003).
73. Adams, C.W. DR5 antibodies and uses thereof. US20060269554 (2006).
74. Li, B., Sidhu, S.S. DR5 antibodies and uses thereof. US20080248037 (2008).
75. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 2010; 16(6): 1701-8.
76. Griffit, T.S., Ratliff, T. Method of inducing tumor cell apoptosis using TRAIL/Apo-2 ligand gene transfer. US6900185 (2005).
77. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001; 61(8): 3330-8.
78. Srivastava, R., Shankar, S., Mackerell, A.D. Methods and compositions of TRAIL-death receptor agonists/activators. US7915245 (2011).
79. Yu R, Mandlekar S, Ruben S, Ni J, Kong AN. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res 2000; 60(9): 2384-9.
80. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosisinducing ligand. Cancer Res 2000; 60(15): 4122-9.
81. Yao GH, Ling LJ, Luan JF, Ye D, Zhu PY, Lei QH. Induction of apoptosis by recombinant soluble human TRAIL in Jurkat cells. Biomed Environ Sci 2007; 20(6): 470-7.
82. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001; 98(3):795-804.
83. Daniel D, Yang B, Lawrence DA, Totpal K, Balter I, Lee WP, et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007; 110(12): 4037-46.
84. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26(21): 3621-30.
85. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28(17): 2839-46.
86. Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 2010; 28(9): 1527-33.
87. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007; 25(29):1390-5.
88. Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008; 14(11): 3450-55.
89. Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, et al. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase I and pharmacokinetic study. J Clin Oncol 2009; 27(26): 4413-21.
90. Mom CH, Verweij J, Oldenhuis CN, Gietema, JA, Fox NL, Miceli R, et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase I study. Clin Cancer Res 2009; 15(17): 5584-90.
91. Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM, et al. A Phase 1b/2 trial of mapatumumab in patients with relapsed/ refractory non-Hodgkin's lymphoma. Br J Cancer 2010; 103 (12): 1783-87.
92. Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C, et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the Tumor necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 2010; 102(3): 506-12.
93. Greco FA, Bonomi P, Crawford J, Kelly, K, Oh Y, Halpern W, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008; 61(1):82-90.
94. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 2010; 16(23): 5883-91.
95. Doi T, Murakami H, Ohtsu A, Fuse N, Yoshino T, Yamamoto N, et al. Phase 1 study of conatumumab, a pro-apoptotic death receptor5 agonist antibody, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 68(3): 733-41.
96. Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 2010; 21(2): 376-81.
97. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13(20): 6187-94.
98. Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010; 16(4): 1256-63.
99. Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C, et al. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 2010; 25(1): 13-9.
100. Ashkenazi A. Directing cancer cells to self-destruct with proapoptotic receptor agonists. Nat Rev Drug Discov 2008; 7(12): 1001-12.
101. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002; 21(15): 2283-94.
102. Dyer MJ, MacFarlane M, Cohen GM. Barriers to effective TRAILtargeted therapy of malignancy. J Clin Oncol 2007; 25(28): 4505-6.
103. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ikegaki N, Brodeur GM. Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Med Pediatr Oncol 2000; 35(6): 603-7.
104. Jonsson G, Paulie S, Grandien A. High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells. Anticancer Res 2003; 23(2B): 1213-18.
105. Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprik MR, et al. Suppression of cFLIP is sufficient to sensitize hu man melanoma cells to TRAIL-and CD95L-mediated apoptosis. Oncogene 2008; 27(22): 3211-20.
106. Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C, et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 2003; 10(3): 356-64.
107. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, et al. Death-receptor O-glycosylation controls tumorcell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13(9): 1070-77.
108. Ashkenazi, A.J., Wagner, K.W. Assays and methods using biomarkers. US20080182277 (2008).
109. Jin X, Wu XX, Abdel-Muneem Nouh MA, Kakehi Y. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin. J Urol 2007; 177(5): 1894-9.
110. Frese S, Brunner T, Gugger M, Uduehi A, Schmid RA. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosisinducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J Thorac Cardiovasc Surg 2002; 123(1): 168-74.
111. Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 2004; 64(14): 4900-5.
112. Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J, et al. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 2005; 3(1): 22.
113. Vignati S, Codegoni A, Polato F, Broggini M. Trail activity in human ovarian cancer cells: Potentiation of the action of cytotoxic drugs. Eur J Cancer 2002; 38(1): 177-83.
114. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 2001; 81(3): 380-90.
115. Mizutani Y, Yoshida O, Miki T, Bonavida B. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Clin Cancer Res 1999; 5(9): 2605-12.
116. Brooks AD, Ramirez T, Toh U, Onksen J, Elliott PJ, Murphy WJ, et al. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. Ann N Y Acad Sci 2005; 1059: 160-7.
117. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003; 22(32): 4953-63.
118. Zhu H, Guo W, Zhang L, Wu S, Teraishi F, Davis JJ, et al. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther 2005; 4(7): 781-6.
119. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007; 12(1): 66-80.
120. Kim SH, Ricci MS, El-Deiry WS. Mcl-1: A gateway to TRAIL sensitization. Cancer Res 2008; 68(7): 2062-4.
121. Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, et al. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: A mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 2007; 282(41): 29831-46.
122. Rosato RR, Almenara JA, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 2007; 67(19): 9490-500.
123. Zangemeister-Wittke U. Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signaling. Ann N Y Acad Sci 2003; 1002: 90-4.
124. Korsmeyer, S.J. BH3 interacting domain death agonist. US5998583 (1999).
125. Ray S, Bucur O, Almasan A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 2005; 10(6): 1411-8.
126. Li R, Ruttinger D, Urba W, Fox BA, Hu HM. Targeting and amplification of immune killing of tumor cells by pro-Smac. Int J Cancer 2004; 109(1): 85-94.
127. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 2002; 277(46): 44236-43.
128. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8(8): 808-15.
129. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL-and TNFalpha-mediated cell death. Science 2004; 305(5689): 1471-4.
130. Alnemri, E.S. IAP binding peptide or polypeptide and methods of using the same. US20020132786 (2001).
131. Shi, Y. Compositions and method for regulating apoptosis. US20020177557 (2001).
132. Debatin, K.M., Fulda, S. Smac peptides as therapeutics against cancer and autoimmune diseases. US20050222387 (2003).
133. Harran, P.G., Wang, X., De Brabander, J.K., Li, L., Thomas, R.M., Suzuki, H. Dimeric small molecule potentiators of apoptosis. US20050197403 (2005).
134. Van Emelen, K., Verdonck, M.G.C., Van Brandt, S.F.A., Angibaud, P.R., Meerpoel, L., Dyatkin, A.B. Inhibitors of histone deacetylase. US20050096468 (2003).
135. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401(6749): 188-93.
136. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/Apo2-L in human malignant tumor cells. Oncogene 2004; 23(37): 6261-71.
137. Guo F, Sigua C, Tao J, Bali P, George P, Li Y, et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004; 64(7): 2580-9.
138. Maier, T., Beckers, T., Baer, T., Vennemann, M., Gekeler, V., Zimmermann, A., Gimmnich, P., Padiya, K., Joshi, H., Joshi, U., Makhija, M., Harel, D. Novel tertrahydro-fused pyridines as histone deacetylase inhibitors. US20110021494 (2011).
139. Bar, T., Maier, T., Beckers, T., Clossek, T., Mahboobi, S., Sellmer, A. Novel bifunctional compounds which inhibit protein kinases and histone deacetylases. US20110065734 (2011).
140. Incoronato M, Garofalo M, Urso L, Romano G, Quintavalle C, Zanca C, et al. miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res 2010; 70(9): 3638-46.
141. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009; 16(6): 498-509.
142. Croce CM. Oncogenes and cancer. N Engl J Med 2008; 358(5): 502-11.